Hombhanje F W
Department of Basic Medical Sciences, Faculty of Medicine, University of Papua New Guinea, Port Moresby.
P N G Med J. 1998 Sep-Dec;41(3-4):112-5.
The standard first-line treatment for malaria in adults in Papua New Guinea is chloroquine; for severe and treatment-failure malaria standard therapy is a combination of quinine and Fansidar (sulphadoxine-pyrimethamine). These standard treatments are currently under revision. The present study evaluated the effect of halofantrine in treatment-failure falciparum malaria in adults in Port Moresby compared to standard therapy. In the halofantrine group all parasites were cleared by day 5 after starting therapy, in the quinine-Fansidar group by day 7. There was no evidence of recurrence of parasitaemia during the 21-day follow-up in either group. Nausea was associated with halofantrine use in 68% of patients. In the quinine-Fansidar group 79% had muffled deafness, 32% tinnitus and 26% dizziness; 32% of patients withdrew from treatment on day 2 because of intolerance to quinine. Halofantrine in this study population provided an efficacy against treatment-failure falciparum malaria similar to that of quinine-Fansidar, with a more favourable profile of adverse effects.
在巴布亚新几内亚，成人疟疾的标准一线治疗药物是氯喹；对于重症和治疗失败的疟疾，标准疗法是奎宁与法西达（磺胺多辛-乙胺嘧啶）联用。目前这些标准治疗方法正在修订。本研究评估了与标准疗法相比，卤泛群治疗莫尔斯比港成人恶性疟治疗失败病例的效果。在卤泛群组，开始治疗后第5天所有疟原虫均被清除，在奎宁-法西达组则是在第7天。两组在21天随访期间均无疟原虫血症复发的迹象。68%使用卤泛群的患者出现恶心症状。在奎宁-法西达组，79%的患者有听力减退，32%有耳鸣，26%有头晕；32%的患者因对奎宁不耐受在第2天退出治疗。在该研究人群中，卤泛群治疗恶性疟治疗失败病例的疗效与奎宁-法西达相似，且不良反应情况更有利。
